Who are Nplate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Doptelet, Mulpleta, Promacta, Nplate, TPO, CsA+ATG+Herombopag.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nplate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Nplate — Competitive Intelligence Brief

Nplate (Nplate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Cardiovascular.

marketed Thrombopoietin receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Nplate (Nplate) — Nantes University Hospital.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nplate TARGET	Nplate	Nantes University Hospital	marketed		Thrombopoietin receptor
Doptelet	AVATROMBOPAG	Akarx Inc	marketed		Thrombopoietin receptor	2018-01-01
Mulpleta	LUSUTROMBOPAG	Vancocin Italia	marketed		Thrombopoietin receptor	2018-01-01
Promacta	ELTROMBOPAG	Novartis	marketed	Thrombopoietin Receptor Agonist	Thrombopoietin receptor	2008-01-01
Nplate	ROMIPLOSTIM	Amgen	marketed	Thrombopoietin Receptor Agonist [EPC]	Thrombopoietin receptor	2008-01-01
TPO	TPO	Shenyang Sunshine Pharmaceutical Co., LTD.	marketed	Thrombopoietin receptor agonist	c-Mpl (thrombopoietin receptor)
CsA+ATG+Herombopag	CsA+ATG+Herombopag	Peking Union Medical College Hospital	marketed	Immunosuppressive agent + thrombopoietin receptor agonist combination	Calcineurin (CsA); T lymphocytes (ATG); thrombopoietin receptor (eltrombopag)

Recent regulatory actions (last 90 days)

2026-03-16 — Promacta · FDA · approved · US · Novartis

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nplate — Competitive Intelligence Brief. https://druglandscape.com/ci/nplate. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab